China CDE Issues Three Key Technical Guidelines to Advance Pharmaceutical Standards

China Center for Drug Evaluation (CDE) has released three technical guidelines addressing critical areas of drug development: biosimilars, Mediterranean anemia gene therapies, and patient-reported outcomes (PRO) in rheumatology/immunology trials. The updates refine regulatory expectations for domestic and international manufacturers.

Biosimilar Labeling Standards

The Technical Guidelines for Biosimilar Drug Labeling (No. 12 of 2025), issued on 10 February 2025, establishes new requirements for biosimilar prescribing information. For the first time, it mandates direct comparability data with reference products in indications, dosage forms, and safety profiles. The guidelines prohibit extrapolation of indications without clinical bridging studies and require explicit disclosure of manufacturing process differences affecting efficacy. This replaces the 2021 draft guidance that lacked specificity on indication extrapolation.

Mediterranean Anemia Gene Therapy Protocols

The Clinical Trial Guidelines for Thalassemia Gene Therapies (No. 11 of 2025) outlines phase III trial design parameters for gene-editing products. Key requirements include:

Minimum 100-patient cohorts with β-thalassemia major
5-year follow-up for delayed adverse events
Standardized vector copy number thresholds (≤2 copies/cell)
Comparative efficacy benchmarks against existing therapies (e.g., transfusions, bone marrow transplant survival rates)

The framework aligns with EMA and FDA gene therapy guidelines but adds China-specific endpoints like hemoglobin stability during seasonal infectious disease peaks.

PRO Requirements for Immune Disease Trials

The PRO Guidelines for Rheumatoid/Immune Disease Trials (No. 10 of 2025) specifies validated patient-reported metrics for regulatory submissions:

Mandatory use of HAQ-DI (Health Assessment Questionnaire Disability Index) in RA trials
Digital PRO collection platforms requiring CDE validation
Minimum 80% PRO compliance thresholds across study phases
Standardized pain scales (0-10 NRS) for all inflammatory conditions

The rules formalize PRO data as secondary endpoints in Phase II and co-primary endpoints in Phase III trials, addressing previous inconsistencies in PRO utilization across China’s clinical trial landscape.

Further Information

Read the original announcements:

For more information on how these updates might impact your development process, contact us to learn about our specialized services for pharmaceutical products in China.